High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 11, 2014, Pages 1583-1590

  Maleki, I ^a   Rastgar, A ^b   Hosseini, V ^a   Taghvaei, T ^a   Rafiei, A ^c   Barzin, M ^b   Torabizadeh, Z ^b   Naghshvar, F ^b   Khalilian, A ^b  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biological markers; C reactive protein; Non alcoholic fatty liver disease; Pentraxine

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PENTRAXIN 3; SERUM AMYLOID P;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; BIOPSY; BLOOD; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY;

ADULT; BIOLOGICAL MARKERS; BIOPSY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; SERUM AMYLOID P-COMPONENT;

EID: 84909645515     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Torres Dm, Harrison Sa. Diagnosis And Therapy Of Nonalcoholic Steatohepatitis. Gastroenterology 2008; 134: 1682-1698
2. Anty R, Iannelli A, Patouraux S, Bonnafous S, Lavallard Vj, Senni-Buratti M, Amor Ib, Staccini-Myx A, Saint-Paul Mc, Berthier F, Huet Pm, Le Marchand-Brustel Y, Gugenheim J, Gual P, Tran A. A New Composite Model Including Metabolic Syndrome, Alanine Aminotransferase And Cytokeratin-18 For The Diagnosis Of Non-Alcoholic Steatohepatitis In Morbidly Obese Patients. Aliment Pharmacol Ther 2010; 32: 1315-1322
3. Wieckowska A, Feldstein Ae. Diagnosis Of Nonalcoholic Fatty Liver Disease: Invasive Versus Noninvasive. Semin Liver Dis 2008; 28: 386-395
4. Bhala N, Jouness Ri, Bugianesi E. Epidemiology And Natural History Of Patients With Nafld. Curr Pharm Des 2013; 19: 5169-5176
5. Tamimi Ti, Elgouhari Hm, Alkhouri N, Yerian Lm, Berk Mp, Lopez R, Schauer Pr, Zein Nn, Feldstein Ae. An Apoptosis Panel For Nonalcoholic Steatohepatitis Diagnosis. J Hepatol 2011; 54: 1224-1229
6. Chitturi S, Wong Vw, Farrell G. Nonalcoholic Fatty Liver In Asia: Firmly Entrenched And Rapidly Gaining Ground. J Gastroenterol Hepatol 2011; 26(Suppl 1): 163-172
7. Hurjui Dm, Nita O, Graur Li, Mihalache L, Popescu Ds, Graur M. The Central Role Of The Non Alcoholic Fatty Liver Disease In Metabolic Syndrome. Rev Med Chir Soc Med Nat Iasi 2012; 116: 425-431
8. Salamone F, Bugianesi E. Nonalcoholic Fatty Liver Disease: The Hepatic Trigger Of The Metabolic Syndrome. J Hepatol 2010: 53: 1146-1147
9. Angulo P, Lindor Kd. Non-Alcoholic Fatty Liver Disease. J Gastroenterol Hepatol 2002; 17(Suppl): S186-190
10. Ghamar Chehreh M, Vahedi M, Pourhoseingholi M, Ashtari S, Khedmat H, Amin M, Zali M, Alavian S. Estimation Of Diagnosis And Treatment Costs Of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation. Hepat Mon 2013; 13: E7382
11. Ekstedt M, Franzen Le, Mathiesen Ul, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Longterm Follow-Up Of Patients With Nafld And Elevated Liver Enzymes. Hepatology 2006; 44: 865-873
12. Adams La, Lymp Jf, St Sauver J, Sanderson So, Lindor Kd, Feldstein A, Angulo P. The Natural History Of Nonalcoholic Fatty Liver Disease: A Populationbased Cohort Study. Gastroenterology 2005; 129: 113-121
13. Wai Ct, Greenson Jk, Fontana Rj, Kalbfleisch Jd, Marrero Ja, Conjeevaram Hs, Lok As. A Simple Noninvasive Index Can Predict Both Significant Fibrosis And Cirrhosis In Patients With Chronic Hepatitis C. Hepatology 2003; 38: 518-526
14. Baranova A, Lal P, Birerdinc A, Younossi Zm. Noninvasive Markers For Hepatic Fibrosis. Bmc Gastroenterol 2011; 11: 91
15. Younossi Zm, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z. Pathologic Criteria For Nonalcoholic Steatohepatitis: Interprotocol Agreement And Ability To Predict Liver-Related Mortality. Hepatology 2011; 53: 1874-1882
16. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T, Lido Study Group. Sampling Variability Of Liver Biopsy In Nonalcoholic Fatty Liver Disease. Gastroenterology 2005; 128: 1898-1906
17. Younossi Zm, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, Rafiq N, Goodman Z, Chandhoke V, Baranova A. A Novel Diagnostic Biomarker Panel For Obesity-Related Nonalcoholic Steatohepatitis (Nash). Obes Surg 2008; 18: 1430-1437
18. Regev A, Berho M, Jeffers Lj, Milikowski C, Molina Eg, Pyrsopoulos Nt, Feng Zz, Reddy Kr, Schiff Er. Sampling Error And Intraobserver Variation In Liver Biopsy In Patients With Chronic Hcv Infection. Am J Gastroenterol 2002; 97: 2614-2618
19. Wieckowska A, Mccullough Aj, Feldstein Ae. Noninvasive Diagnosis And Monitoring Of Nonalcoholic Steatohepatitis: Present And Future. Hepatology 2007; 46: 582-589
20. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet Mc, Konate A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A Novel Panel Of Blood Markers To Assess The Degree Of Liver Fibrosis. Hepatology 2005; 42: 1373-1381
21. Festi D, Schiumerini R, Marzi L, Di Biase Ar, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A. The Diagnosis Of Non-Alcoholic Fatty Liver Disease-Availability And Accuracy Of Non-Invasive Methods. Aliment Pharmacol Ther 2013; 37: 392-400
22. Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive Investigations For Non Alcoholic Fatty Liver Disease And Liver Fibrosis. World J Gastroenterol 2010; 16: 4784-4791
23. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. High-Sensitivity C-Reactive Protein Is An Independent Clinical Feature Of Nonalcoholic Steatohepatitis (Nash) And Also Of The Severity Of Fibrosis In Nash. J Gastroenterol 2007; 42: 573-582
24. Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, Mawatari H, Iida H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Kobayashi N, Kubota K, Saito S, Maeyama S, Sagara M, Aburatani H, Kodama T, Nakajima A. Plasma Pentraxin3 Is A Novel Marker For Nonalcoholic Steatohepatitis (Nash). Bmc Gastroenterol 2008; 8: 53
25. Sanyal Aj, American Gastroenterological, Association. Aga Technical Review On Nonalcoholic Fatty Liver Disease. Gastroenterology 2002; 123: 1705-1725
26. Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T. Global Analysis Of Rna Expression Profile In Human Vascular Cells Treated With Statins. J Atheroscler Thromb 2004; 11: 62-72
27. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Kubota I. Pentraxin 3, A New Marker For Vascular Inflammation, Predicts Adverse Clinical Outcomes In Patients With Heart Failure. Am Heart J 2008; 155: 75-81
28. Kravitz Ms, Shoenfeld Y. Autoimmunity To Protective Molecules: Is It The Perpetuum Mobile (Vicious Cycle) Of Autoimmune Rheumatic Diseases? Nat Clin Pract Rheumatol 2006; 2: 481-490
29. Kleiner De, Brunt Em, Van Natta M, Behling C, Contos Mj, Cummings Ow, Ferrell Ld, Liu Yc, Torbenson Ms, Unalp-Arida A, Yeh M, Mccullough Aj, Sanyal Aj. Design And Validation Of A Histological Scoring System For Nonalcoholic Fatty Liver Disease. Hepatology 2005; 41: 1313-1321
30. Kleiner De, Brunt Em. Nonalcoholic Fatty Liver Disease: Pathologic Patterns And Biopsy Evaluation In Clinical Research. Semin Liver Dis 2012; 32: 3-13
31. Brunt Em, Janney Cg, Di Bisceglie Am, Neuschwander-Tetri Ba, Bacon Br. Nonalcoholic Steatohepatitis: A Proposal For Grading And Staging The Histological Lesions. Am J Gastroenterol 1999; 94: 2467-2474
32. Dowman Jk, Tomlinson Jw, Newsome Pn. Systematic Review: The Diagnosis And Staging Of Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-540.